Biotech Startups

X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia. It is a publicly traded company listed on Nasdaq.

4 investors

XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage. The company's lead program, XC001, targets refractory angina in patients with limited treatment options.

4 investors

AmicaTerra manufactures bioplastic products from edible and non-edible plant materials, achieving cost-competitive performance through processing at Taiwan facilities. The company aims to supply these sustainable biomass-based materials globally, with plans to establish production in Japan using agricultural waste and bamboo resources.

4 investors

Alivexis is a drug discovery company developing small-molecule targeted therapeutics by combining biology research with a computational technology platform. It operates as an international team with pharmaceutical, biotechnology, and computational R&D experience.

4 investors

MOLCURE uses proprietary large language models, physics-based simulations, and experimental data from its in-house biolab to discover antibody and peptide biotherapeutics against difficult targets. It offers an AI-driven drug discovery platform covering high-throughput screening, next-generation sequencing, de novo molecule discovery, and lead optimization for pharmaceutical partners.

4 investors

PURMX Therapeutics develops nucleic acid medicines as anti-cancer drugs based on microRNA research and the concept of an "ageing switch" to induce ageing in cancer cells. The Japanese pharmaceutical venture handles drug development functions including non-clinical research, clinical development, CMC, and regulatory affairs.

4 investors

PRISM BioLab is a biotechnology company that develops PepMetics, a proprietary drug discovery platform of small molecules designed to mimic α-helix or β-turn peptides, aiming to target proteins previously considered "undruggable." The company maintains a screening library of over 20,000 compounds and partners with pharmaceutical firms on drug discovery programs.

3 investors

10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers. The tools support applications in cancer, immunology, and neuroscience, enabling gene expression and multiomic profiling of cell surface protein, intracellular protein, and CRISPR guides.

3 investors

1849 bio engineers microorganisms to make metal extraction from low-grade copper and gold ores economically viable for mining operations. The company applies advanced bioengineering techniques to develop microbes capable of processing ore types that existing biomining processes cannot handle, targeting the hundreds of billions of dollars in copper currently considered uneconomical to extract.

3 investors

3T Biosciences develops TCR-based immunotherapies for cancer using a proprietary platform that combines machine-learning algorithms with immunological research to identify and validate T cell receptor targets. The company creates therapeutic treatments targeting cancer and other difficult-to-treat diseases.

3 investors

3 investors

5Metis is a discovery-stage company developing boron-based molecules for crop protection, running medicinal/discovery chemistry and toxicity testing programs to invent new agricultural active ingredients. Its R&D team is based in Research Triangle Park, North Carolina.

3 investors

A-SEEDS is a Shinshu University spin-out developing non-viral gene-modified immune cell therapies, including non-viral CAR-T cell products, to treat pediatric and young-adult cancers, including solid tumors, that lack effective treatments. The company focuses on advancing basic research through non-clinical development into clinical application of these cancer cell therapies.

3 investors

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs that inhibit hunger to treat metabolic diseases. Its lead compound, ARD-101, is an oral investigational drug for hunger-associated rare diseases that activates bitter taste receptors in the gut to trigger satiety signals, with potential applications in hyperphagia and obesity.

3 investors

Abalone Bio develops target-activating antibodies for difficult-to-drug disease targets by combining engineered biology with machine learning. The company uses large-scale biological measurement platforms and AI-powered sequence analysis to discover functional antibody drugs for pharmaceutical and biotechnology applications.

3 investors

AbolerIS Pharma develops therapeutic approaches that regulate the immune system by inducing immune tolerance while preserving useful immune responses, targeting inflammatory, autoimmune, and degenerative diseases. It is a biotech company working on drug candidates based on regulatory T cell research.

3 investors

Abzena is an integrated CDMO and CRO providing end-to-end development and cGMP manufacturing services for complex biologics and bioconjugates, including ADCs, AOCs, bispecifics, and HPAPIs. It serves biotech, academic, and pharmaceutical customers across the drug development lifecycle from discovery through commercial manufacturing.

3 investors

Acrivon develops targeted precision oncology therapies matched to patients through its proteomics-based patient selection method, aiming to treat common solid cancers. Its pipeline includes clinical-stage kinase inhibitors for DNA Damage Response, cell cycle, and transcriptional regulator targets.

3 investors

Actithera develops radioligand therapies (RLT) for cancer, using proprietary molecular design and chemistry to create compounds that concentrate in tumors while sparing healthy tissue. The company designs molecules that match radionuclide half-life with tumor residence time to enable effective treatment with fewer therapy cycles, with some compounds being prepared for clinical trials.

3 investors

Adagene is a clinical-stage immunotherapy company that uses computational biology and artificial intelligence to discover and design therapeutic antibodies for cancer treatment. The company's platform generates novel antibodies aimed at improving safety and efficacy in precision-guided antibody-drug conjugates and other therapeutic approaches.

3 investors

Adaptyx develops a minimally-invasive wearable dermal patch that continuously measures biomarkers in interstitial fluid using an array of programmable molecular switches. The continuous data feeds algorithms intended to help clinicians make timelier decisions and reduce avoidable complications and hospital readmissions, replacing traditional lab draws and repeat clinic visits.

3 investors

ADARx is a clinical-stage biopharmaceutical company developing RNA-based medicines using its RNA science expertise and proprietary targeted delivery platforms to silence disease-causing genes. Its pipeline targets chronic conditions including genetic, complement-mediated, cardiovascular, cardiometabolic, central nervous system, and metabolic diseases.

3 investors

Adcentrx Therapeutics is a biotech company focused on the discovery and clinical development of antibody-drug conjugates (ADCs) for oncology. It develops site-specific ADC therapeutics and supporting platform technology for cancer treatment.

3 investors

Adela develops blood-based diagnostic tests that analyze cell-free DNA using whole methylome analysis to detect and monitor cancer. It serves clinicians and biopharma partners with applications including early multi-cancer detection, minimal residual disease detection, and immunotherapy response monitoring.

3 investors